Recurrence clinical trials

CAR-NK cell therapy for recurrent glioblastoma

This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.

CAR-NK cell therapy for recurrent ovarian cancer

This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins often found on ovarian cancer cells. It is for people whose cancer has come back after at least two prior treatments.

Urinary tract health and microbiome study

This study looks at how bacteria and the immune system affect the lower urinary tract. It includes healthy volunteers and people with various urinary conditions, like infections or bladder pain.

CapsuleX and cisplatin for platinum-resistant ovarian cancer

This study tests a new treatment combination (CapsuleX plus cisplatin) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help when the cancer has progressed within 6 months of last platinum treatment.

Heart Rhythm Treatment Success Tracking Study

This study follows patients getting a newer heart rhythm treatment called pulsed field ablation for atrial fibrillation (an irregular heartbeat). Researchers want to understand which patients do well long-term and which may need additional treatment.

New drug YSCH-01 with immunotherapy for recurrent brain cancer

This early-stage trial tests a new drug called YSCH-01, alone or combined with an immunotherapy drug (atezolizumab), for glioblastoma that has come back after previous treatment. The study places a small tube in the brain to deliver the drug directly and monitors safety and how well it works.

Sitagliptin for recurrent grade 4 glioma

This trial tests whether the diabetes drug sitagliptin (Januvia) can help slow or shrink a recurrent grade 4 glioma (a type of brain tumor). It's for people whose tumor has come back after standard treatment and who have not used sitagliptin or Avastin before.

CAR-NK cells for recurrent glioblastoma and high-grade brain tumors

This trial tests a new type of immune cell therapy called CAR-NK cells to treat glioblastoma or high-grade glioma that has come back or gotten worse after standard treatment. The cells are engineered to recognize and attack tumor cells in the brain.

Brain Training During CAR-T Cell Cancer Treatment

This study tests whether special brain exercises can help protect thinking and memory skills during CAR-T cell therapy—a newer cancer treatment for certain blood cancers. Researchers want to see if training your brain during treatment reduces side effects on memory and mental function.

CAR-NK Cell Therapy for Recurrent Ovarian Cancer

This trial tests a new type of cell therapy using modified natural killer cells (CAR-NK cells) that are trained to attack ovarian cancer cells. It's designed for patients whose cancer has come back or stopped responding to previous treatments.

CAR-NK Cell Therapy for Advanced Head and Neck Cancer

This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.

Testing a cell therapy for recurrent ovarian cancer

This trial tests a treatment where doctors take immune cells from your tumor, grow more of them in the lab, and put them back into your body to fight the cancer. This approach, called TIL therapy, aims to strengthen your own immune system to target ovarian cancer that has come back.

Cold plasma to lower risk of chronic subdural hematoma coming back

This trial tests if a special cold plasma treatment applied during surgery can reduce the chance of a chronic subdural hematoma (a slowly growing blood collection on the brain) from returning. It may help people who already need surgery for this condition.

Drug combination before surgery for recurrent head and neck cancer

This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.

Predicting cancer return after penis-sparing surgery for penile cancer

This study looks at how often penile cancer comes back after low-risk, penis-sparing surgery and how that affects long-term health. It may help doctors understand which patients need closer follow-up.

Olaparib plus pembrolizumab and bevacizumab after ovarian cancer

This trial tests whether adding olaparib, pembrolizumab, and bevacizumab as ongoing (“maintenance”) treatment can help control platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer that has responded to prior chemotherapy. It focuses on people whose tumors do NOT have BRCA1/2 gene mutations.

APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors

Testing fianlimab with cemiplimab for head and neck cancer

This study compares a new combination of two drugs (fianlimab and cemiplimab) against cemiplimab alone for people with head and neck cancer that has returned or spread. It aims to see if the combination works better.

Hormone therapy with or without chemo for early breast cancer

This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.

Test targeted radiation to treat recurrent ventricular tachycardia

This trial studies a radiation approach (called stereotactic body radiation therapy, or SBRT) to treat ventricular tachycardia (a dangerous heart rhythm) that keeps coming back. It aims to reduce the rhythm episodes in people who have already tried catheter ablation (a procedure to cauterize rhythm sources) or cannot have it.

Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways

Study of 8-chloroadenosine plus venetoclax for relapsed or refractory AML

This trial tests a combination of two drugs, 8-chloroadenosine and venetoclax, for people with acute myeloid leukemia (AML) that has come back or not responded to prior treatments. The goal is to see if this combination can help control the leukemia.

Testing Avastin added to chemo plus Keytruda for certain endometrial cancer

This study tests adding Avastin (bevacizumab) to the standard combination of chemotherapy (carboplatin and paclitaxel) plus immunotherapy (Keytruda) for advanced or recurrent endometrial cancer with a specific genetic makeup (pMMR and TP53 mutation). The goal is to see if adding Avastin helps shrink tumors or slow their growth.

Study of Dato-DXd with or without durvalumab for advanced triple-negative breast cancer

This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.